Research summary ·
Recurrent miscarriage and thrombosis in Asian antiphospholipid syndrome: a systematic review.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This was a review of earlier studies on antiphospholipid syndrome, or APS. APS is an immune illness that makes blood clot too easily. It can also cause repeated pregnancy loss. The team pulled together 22 studies from Asian countries. Together these studies covered more than 40,000 people. These included national records and high-risk groups, such as people with lupus.
What they found
In South Korea and Taiwan, APS was rare in the general public. It was more common in women than in men. APS was found more often in women with repeated pregnancy loss. In Japan, 5708 women were tested for the linked antibodies. Clot-preventing treatment was linked to more live births in pregnant women with APS. Blood clots were common in people with APS. Clots in veins and in arteries showed up at similar rates. Stroke stood out in people with both lupus and APS. The abstract also says how often a very severe form of APS occurred. Clots came back each year in some patients.
What it means for patients
The authors say APS is rare in Asia overall. But when it occurs, it brings a heavy load of pregnancy loss and clots. They suggest testing for these antibodies in women with unexplained repeated pregnancy loss. They see this as a useful way to improve pregnancy results in Asia.
Why it is not certain yet
This review pulled together different kinds of studies and patient groups. The abstract notes that data from Asia are still patchy. Results came from only some Asian countries. The abstract does not say how strong each study was. The link between treatment and live births shows a link, not proof of cause. A review can only be as good as the studies in it.
Source
Recurrent miscarriage and thrombosis in Asian antiphospholipid syndrome: a systematic review.
PubMed · PMID 42497671We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Antiphospholipid syndrome publications